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 Patients with end-stage renal disease (ESRD) receiving dialysis can have altered 
nutritional status and body composition due to dietary restrictions, level of physical activity, 
co-morbidities, metabolic alterations and inflammation.1 As such, weight loss or wasting is 
common among this population with up to 75% of adults with ESRD undergoing maintenance 
dialysis displaying some evidence of wasting.2 There are several forms of loss of lean muscle 
mass or wasting in ESRD, including ‘protein energy wasting’, ‘cachexia’, and ‘age-related 
sarcopenia’ and these terms are often used interchangeably alongside ‘malnutrition’ in current 
care. Limited understanding of the differences between such terms is arguably a barrier to ac-
curate recognition and management of these disorders in patients with ESRD. For instance, a 
recent European study of over 700 dietetic participants concluded that only 13% of health care 
professionals who could differentiate between malnutrition, starvation, cachexia and sarcope-
nia.3 Such knowledge is pertinent as for example, loss of muscle mass is a key feature in both 
sarcopenia and cachexia, but most patients with sarcopenia are not cachectic,4 as muscle wast-
ing occurs with aging.
 Research has informed a disease specific definition (and associated diagnostic criteria) 
for protein energy wasting (PEW) in renal disease, and while cachexia in ESRD is seen as the 
severe form of PEW,5 there remains no consensus definition or diagnostic criteria to differenti-
ate between PEW and cachexia. What distinguishes PEW from cachexia is that the latter relates 
to only severe forms of metabolic depletion. However, PEW can refer to mild reduction of lean 
muscle and depletion of energy stores.6 Alongside, the lack of disease specific definition or 
diagnostic criteria for cachexia, there is also no such disease specific criterion for sarcopenia 
in renal disease. The evidence-based development of these terms is essential to enable health 
care professionals to clearly identify and differentiate between such conditions. This greater 
understanding of the difference and interplay between cachexia, PEW and sarcopenia in ESRD 
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Sarcopenia of old age9 Cachexia in chronic illness10 Protein energy wasting in renal disease5,11
 (i) Weight
Not stated, but weight gain is 
expected in obese sarcopenia 
whereas weight loss can occur 
otherwise
Oedema-free “unintentional” weight loss of at least 
5% in 12 months or less in the presence of  
underlying illness.
In cases where weight loss cannot be documented, 
a BMI<18.5 kg/m2 or a drop from higher BMI to a 
BMI<20 kg/m2 is sufficient.
Unintentional weight loss over time: 5% over 3 
months or 10% over 6 months.
Oedema-free BMI<23 kg/m2 for example,  
post-dialysis dry weight. 
(ii) Biochemistry
Not stated, but it is expected 
that serum creatinine relative to 
kidney function declines.
Increased inflammatory markers CRP (>3.0 mg/L), 
IL-6>3.0 pg/mL).
Anaemia (<10 g/dL).
Low serum albumin (<3.5 g/dl BGG or <3.2 BCP)
Serum albumin<3.8 g/dl (bromocresol green). 
Serum prealbumin (transthyretin)<30 mg/dL (for 
maintenance dialysis patients only; levels may 
vary according to GFR level for patients with 
CKD stages 2-5).
Serum cholesterol<100 mg/dL
(iii) Muscle and/or 
fat mass
Low muscle mass<7.23-7.26 kg/
m2 for men and<5.5-5.67 kg/m2 
for women using appendicular 
lean tissue/height2 by DEXA12
Low fat-free mass index.
Lean tissue depletion i.e. mid upper arm muscle 
circumference<10th percentile for age and gender); 
appendicular skeletal muscle index by DEXA <5.45 
kg/m2 in females and<7.25 kg/m2 in males.
Total body fat percentage<10%. 
Reduced mid-arm muscle circumference area - 
reduction >10% in relation to 50th percentile of 
reference population.
Muscle wasting: reduced muscle mass 5% over 
3 months or 10% over 6 months. 
Indirect measure of muscle mass, such as serum 
creatinine.
(iv) Muscle strength
Low muscle strength, handgrip 
strength<20 kg women and<30 
kg men.
Decreased muscle strength (lowest tertile). Not stated
(v) Functionality Gait speed<0.8 metres per second.
Presence of fatigue - defined as physical and/or 
mental weariness, resulting from exertion; an inability 
to continue exercise at the same intensity with a 
resultant deterioration in performance.
Not stated
(vi) Dietary intake
Not stated, but often some 
decline in appetite and/or protein 
and energy is observed.
Anorexia.
Limited food intake (i.e. total energy intake<20 kcal/
kg /day; <70% of usual food intake) or poor appetite.
Unintentional low dietary protein intake<0.80 g/
kg/day for at least 2 months for dialysis patients 
or<0.6 g/kg/day for patients with CKD stages 2-5. 
Unintentional low dietary energy intake<25 Kcal/
kg/day for at least 2 months.
Diagnosis Person must have column iii plus column iv or v.
Person must have column i plus three of the  
remaining five columns ii,iii,iv,v,or vi.
Person must have at least three out of the four  
columns i,ii,iii and vi  and at least one test from 
each of the selected columns.
has the potential to inform the development and testing of targeted novel therapeutic treatments aimed at reducing morbidity and 
mortality.7 Significant progress has been made defining cachexia and its associated clinical characteristics in patients with cancer. An 
agreed definition and classification of cancer cachexia8 has contributed to enhanced standardization of screening, staging assessment 
and management. This is a model that could be applied to cachexia in other chronic conditions, such as ESRD.
 
 Reflecting the current evidence base, Table 1 outlines the characteristics of age-related sarcopenia, cachexia in chronic 
illness, and PEW in renal disease. These characteristics and associated pathologies are reviewed elsewhere in the literature,5,9-11 
and while the diagnostic criteria share similarities they are not identical. For example, weight loss is part of the definition of both 
cachexia in chronic illness and PEW in renal disease, but the duration of the weight loss differs (weight loss of 5% over 6 months 
in cachexia as opposed to 5% over 3 months in PEW). Additionally, the diagnostic criteria for cachexia in chronic illness empha-
sizes lean mass functionality (decreased muscle strength and fatigue), which is also common in sarcopenia of old age, although the 
defining characteristics of sarcopenia emphasize the importance of gait speed which cachexia does not. Furthermore, anaemia is 
considered a feature of cachexia in chronic illness, but not of PEW in renal disease or sarcopenia of old age.
 As seen in Table 1, there are both variations and commonalities in the known clinical characteristics of sarcopenia, cachexia 
and PEW in a renal population. This may be reflective of the poly-symptomatic nature of ESRD. However, it makes the diagnosis 
of any of the three conditions more complex. Effectively distinguishing between these three conditions in ESRD is important, ac-
knowledging that elements of sarcopenia and PEW may be present in cachexia, as interventional strategies may be very different for 
each. Work on delineating key clinical characteristics of PEW in renal disease has progressed extensively13 and cachexia is viewed 
as a severe form of PEW.5 However, the diagnostic criteria for cachexia in ESRD, as opposed to PEW, have not been agreed. This 
is significant as cachexia may involve additional metabolic abnormalities that are potentially amenable to therapeutic intervention.
Table 1: Defining characteristics of sarcopenia of old age, cachexia in chronic illness and protein-energy wasting in renal disease.
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 What should the next steps be? Adoption of a disease-specific definition of cachexia in ESRD would contribute to standard-
ization of screening, assessment and management strategies that are aimed at improving morbidity and mortality in these patients. 
Such a definition needs to be derived in such a way to distinguish cachexia from both sarcopenia and PEW, should define a popula-
tion group with a different prognosis from PEW, and needs to reflect our understanding of the pathophysiology (particularly the role 
of inflammation) of cachexia in other conditions such as cancer, heart failure and COPD. Such a definition would greatly facilitate 
screening, diagnosis and development of treatments for this life-limiting complication of end stage renal disease.
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